{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:17:59Z","timestamp":1790983079169,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,10]]},"DOI":"10.7759\/cureus.114295","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T18:40:02Z","timestamp":1786387202000},"source":"Crossref","is-referenced-by-count":1,"title":["Obinutuzumab for Rituximab-Intolerant Minimal Change Disease: A Case Report and Review of Recent Literature"],"prefix":"10.7759","author":[{"given":"Hui Yi","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman M","year":"2007","unstructured":"Waldman M, Crew RJ, Valeri A, et al.. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007, 2:445-453. 10.2215\/CJN.03531006","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie RA","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, et al.. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025, 392:1471-1483. 10.1056\/NEJMoa2410965","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2602678","article-title":"Obinutuzumab or tacrolimus in primary membranous nephropathy","author":"Fervenza FC","year":"2026","unstructured":"Fervenza FC, Hou FF, Hao CM, et al.. Obinutuzumab or tacrolimus in primary membranous nephropathy. N Engl J Med. 2026, 10.1056\/NEJMoa2602678","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0307981","article-title":"Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: a systematic review and meta-analysis","volume":"19","author":"Wong ZY","year":"2024","unstructured":"Wong ZY, Teo CY, Fiona Wong YQ, Ng KT, Lim SK. Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: a systematic review and meta-analysis. PLoS One. 2024, 19:e0307981. 10.1371\/journal.pone.0307981","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.19316","article-title":"Rituximab for relapsing nephrotic syndrome in adults: a randomized clinical trial","volume":"334","author":"Isaka Y","year":"2025","unstructured":"Isaka Y, Sakaguchi Y, Shinzawa M, et al.. Rituximab for relapsing nephrotic syndrome in adults: a randomized clinical trial. JAMA. 2025, 334:2011-2019. 10.1001\/jama.2025.19316","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S302257","article-title":"Consolidation treatment and long-term prognosis of rituximab in minimal change disease and focal segmental glomerular sclerosis","volume":"15","author":"Lin L","year":"2021","unstructured":"Lin L, Wang W, Wu Y, et al.. Consolidation treatment and long-term prognosis of rituximab in minimal change disease and focal segmental glomerular sclerosis. Drug Des Devel Ther. 2021, 15:1945-1953. 10.2147\/DDDT.S302257","journal-title":"Drug Des Devel Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109265","article-title":"Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents","volume":"248","author":"Looney CM","year":"2023","unstructured":"Looney CM, Strauli N, Cascino MD, et al.. Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents. Clin Immunol. 2023, 248:109265. 10.1016\/j.clim.2023.109265","journal-title":"Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang WY","year":"2005","unstructured":"Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005, 36:3-10. 10.1016\/j.ymeth.2005.01.001","journal-title":"Methods"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300647","article-title":"Cross-reactivity of antibodies to rituximab with other therapeutic anti-CD20 antibodies","volume":"212","author":"Rispens T","year":"2024","unstructured":"Rispens T, Kuijpers TW, Killestein J, van Kempen ZL, Bloem K. Cross-reactivity of antibodies to rituximab with other therapeutic anti-CD20 antibodies. J Immunol. 2024, 212:529-533. 10.4049\/jimmunol.2300647","journal-title":"J Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000541972","article-title":"Obinutuzumab may be an effective and safe option for adult minimal change disease and focal segmental glomerulosclerosis patients after multitarget therapy including rituximab","volume":"56","author":"Lin Y","year":"2025","unstructured":"Lin Y, Pan Y, Han Q, et al.. Obinutuzumab may be an effective and safe option for adult minimal change disease and focal segmental glomerulosclerosis patients after multitarget therapy including rituximab. Am J Nephrol. 2025, 56:111-120. 10.1159\/000541972","journal-title":"Am J Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2026.106497","article-title":"Efficacy of obinutuzumab for frequently relapsing or steroid-dependent nephrotic syndrome","volume":"11","author":"Li Y","year":"2026","unstructured":"Li Y, Hu H, Ai Y, et al.. Efficacy of obinutuzumab for frequently relapsing or steroid-dependent nephrotic syndrome. Kidney Int Rep. 2026, 11:106497. 10.1016\/j.ekir.2026.106497","journal-title":"Kidney Int Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521354-obinutuzumab-for-rituximab-intolerant-minimal-change-disease-a-case-report-and-review-of-recent-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T18:40:03Z","timestamp":1786387203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521354-obinutuzumab-for-rituximab-intolerant-minimal-change-disease-a-case-report-and-review-of-recent-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.114295","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,10]]}}}